KCT0005020
Recruiting
未知
A 8 week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of CTE on Stomach Symptom
ConditionsDiseases of the digestive system
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of the digestive system
- Sponsor
- Konkuk University Medical Center
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Age: 20\-70
- •2\) Functional dyspepsia by the Rome committe for functional gastrointestinal disorder criteria IV\+)
- •\*Diagnoses if at least one of the following symptoms is present and there is no abnormal cause in an examination including the upper digestive endoscope (if the symptom starts 6 months prior to Visit 1 and has been present for the last 3 months).
- •\-bothersome postprandial fullness
- •\-bothersome early satiation
- •\-bothersome epigastric pain
- •\-bothersome epigastric burning
- •3\) GIS(Gastrointestinal Symptom) questionnaire: 4 symptoms among the 10 symptoms , more than 12 points(5\-point Likert scale)
- •4\) A person who agrees to participate in this human application test and signs a written agreement before the test begins.
Exclusion Criteria
- •1\) In a gastroscopy, an abnormal condition was confirmed. (However, it can be replaced by a test result within 10 months).
- •2\) A person with a history of severe malignant tumors, cerebrovascular diseases (brain infarction, cerebral hemorrhage, etc.) and heart diseases (myocardial infarction, heart failure, arrhythmia requiring treatment) within six months of visit 1 (but, in the case of a clinically stable human application test, he or she may participate in the test.)
- •3\) A person who has a history of peptic ulcer within six months of visiting1
- •4\) Persons with a gastrointestinal surgery history (excluding appendectomy and hemorrhoidectomy)
- •5\) Patients with a history of malignant tumors in gastrointestinal tract
- •6\) A person who has taken H2 receptor blocker, anti\-choline (Muscarin receptor antagonist), gastrin receptor antagonist, prostagladdin drug, proton pump inhibitor, gastrointestinal protection agent, other health\-related health\-functioning food within two weeks of visit1;
- •7\) A person who is required to continue to take drugs that can cause gastritis, such as adrenal cortical hormones, nonsteroidal anti\-inflammatory drugs and aspirin, during the test period.
- •8\) A person who has an average alcohol intake habit of 14 unit per week and 7 unit per week over the past month in a drinking habit survey.
- •9\) Patients with unregulated hypertension (measuring standard after 10 minutes stabilization of the person subject to human application test) (above 160mmHg of blood pressure in the retractor or 100mmHg of blood pressure in the retractor).
- •10\) Unregulated diabetics (above 180 mg/dl of fasting blood sugar)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Clinical Trial for the Evaluation of the Efficacy and Safety of MJBIO-002 on Vaginal HealthKCT0004975Konkuk University Medical Center100
Recruiting
Not Applicable
Clinical evaluation of extract of Ecklonia cava Kjellman on gingival healthKCT0005397Duksung Women's University50
Completed
Not Applicable
A 8 week, Multi-center, Randomized, Double-Blind, Placebo-Controlled Human Study for the Evaluation of the Efficacy and Safety of PMEC on Gingival healthKCT0008940MedibioLAB100
Recruiting
Not Applicable
A 8 week, multi-center, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of Magnolia extract on gingival healthKCT0006746O100
Completed
Not Applicable
A 8 week, multi-center, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of MAEC on gingival healthCongenital malformations, deformations and chromosomal abnormalitiesKCT0005569MedibioLAB100